Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 4/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.35 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10689263 | 1.00 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9806651 | 0.97 | TDP1 (0.47) | CYP3A4TDP1KDM4EGAAESR1 | |
| SCHEMBL31242726 | 0.97 | CYP3A4 (0.47) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9815434 | 0.97 | TDP1 (0.47) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL11017606 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL10603455 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL1450045 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL17008412 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL19460486 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 | |
| Hydrochloric Acid SCHEMBL9803750 | 0.94 | CYP3A4 (0.45) | CYP3A4TDP1KDM4EGAAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022252789-A1 | METHOD FOR PREPARING JAK INHIBITOR KEY INTERMEDIATE | 山东莱福科技发展有限公司 | 2022-12-08 | — | — | WO | claimed |
| EP-3275881-B1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2021-08-04 | — | — | EP | claimed |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-10-16 | — | — | US | claimed |
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | claimed |
| EP-3275881-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | claimed |
| US-9708432-B2 | Highly sensitive (meth)acrylate and radical curable material | AUTONETWORKS TECHNOLOGIES, LTD. (JP) | 2017-07-18 | — | — | US | claimed |
| US-9611337-B2 | Chain transfer agent, photosensitive composition, cured product of photosensitive composition, and method for curing photosensitive composition | AUTONETWORKS TECHNOLOGIES, LTD. (JP) | 2017-04-04 | — | — | US | claimed |
| EP-2083033-B1 | Organic semiconducting copolymer and organic electronic device including the same | SAMSUNG ELECTRONICS CO LTD (KR) | 2012-04-18 | — | — | EP | claimed |
| EP-1846472-B1 | PROCESS OF PREPARING REGIOREGULAR POLYMERS | MERCK PATENT GMBH (DE) | 2011-03-23 | — | — | EP | claimed |
| US-7807776-B2 | Procees of preparing regioregular polymers | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-05 | — | — | US | claimed |
| US-20050080219-A1 | Process of preparing regioregular polymers | MERCK PATENT GMBH (DE) | 2005-04-14 | — | — | US | claimed |
| US-20040030091-A1 | Lightweight, electroconductivity, heat resistance | MCCULLOUGH RICHARD D (US) | 2004-02-12 | — | — | US | claimed |
| US-20040024171-A1 | Stereospecific electroconductive polymers such as polyhexylthiophene-polystyrene or -polymethylacrylate copolymers, used as light emitting diodes, biosensors, transistors, displays or optical apparatus | MCCULLOUGH RICHARD D (US) | 2004-02-05 | — | — | US | claimed |
| US-6602974-B1 | Conducting polymers, head-to-tail coupled regioregular polythiophenes, poly-(3-substituted) thiophene diol | CARNEGIE MELLON UNIVERSITY | 2003-08-05 | — | — | US | claimed |
| EP-0973784-B1 | PREPARATION OF TERTIARY PHOSPHINES VIA NICKEL-CATALYZED CROSS COUPLING | PCBU SERVICES INC (US) | 2002-01-16 | — | — | EP | claimed |
| US-6166172-A | Method of forming poly-(3-substituted) thiophenes | CARNEGIE MELLON UNIVERSITY (US) | 2000-12-26 | — | — | US | claimed |
| EP-1028136-A2 | A method of forming poly-(3-substituted) thiophenes | CARNEGIE-MELLON UNIVERSITY (US) | 2000-08-16 | — | — | EP | claimed |
| US-5874628-A | Method for preparation of tertiary phosphines via nickel-catalyzed cross coupling | MONSANTO COMPANY (US) | 1999-02-23 | — | — | US | claimed |
| EP-0532515-B1 | PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0619806-B1 | PREPARATION OF SUBSTITUTED PIPERIDINES | PFIZER (US) | 1996-01-03 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118739-A1 | COMPOUND OF 5-HYDROXYL-1,7-NAPHTHYRIDINE SUBSTITUTED BY ARYLOXY OR HETEROARYLOXY, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HIF1AN, EGLN3, EGLN2 | CYP3A4 82/4885TDP1 4547/4885KDM4E 673/4885 |
| US-10100051-B2 | Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof | HIF1AN, EGLN3, EGLN2 | CYP3A4 82/4885TDP1 4547/4885KDM4E 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.